{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:05:23Z","timestamp":1790345123771,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40273-026-01638-9","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:26:04Z","timestamp":1783535164000},"page":"1189-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4497-0926","authenticated-orcid":false,"given":"Thomas S.","family":"Clemmet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-9093","authenticated-orcid":false,"given":"Duc Binh","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2097-5951","authenticated-orcid":false,"given":"Alice","family":"Copson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z. N.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9339-7374","authenticated-orcid":false,"given":"Gabriel","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"3","key":"1638_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176(3):650\u20138. https:\/\/doi.org\/10.1111\/bjd.15021.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1638_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1638_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","volume":"14","author":"F Alinaghi","year":"2020","unstructured":"Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - a systematic review and meta-analysis. J Crohns Colitis. 2020;14(3):351\u201360. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz152.","journal-title":"J Crohns Colitis"},{"issue":"13","key":"1638_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(13):1670\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.009.","journal-title":"J Am Coll Cardiol"},{"key":"1638_CR5","doi-asserted-by":"publisher","first-page":"1593003","DOI":"10.3389\/fmed.2025.1593003","volume":"12","author":"Z Li","year":"2025","unstructured":"Li Z, Gu Z, Xiang J, Zhang X. The incidence of metabolic syndrome in psoriasis patients and its correlation with disease activity: a systematic review and meta-analysis. Front Med (Lausanne). 2025;12:1593003. https:\/\/doi.org\/10.3389\/fmed.2025.1593003.","journal-title":"Front Med (Lausanne)."},{"key":"1638_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fpsyg.2016.00087","volume":"7","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Evers AW, Bundy C, Kimball AB. Getting under the skin: report from the international psoriasis council workshop on the role of stress in psoriasis. Front Psychol. 2016;7:87. https:\/\/doi.org\/10.3389\/fpsyg.2016.00087.","journal-title":"Front Psychol"},{"key":"1638_CR7","doi-asserted-by":"publisher","first-page":"adv00699","DOI":"10.2340\/actadv.v102.1991","volume":"102","author":"B Halioua","year":"2022","unstructured":"Halioua B, Chelli C, Misery L, Taieb J, Taieb C. Sleep disorders and psoriasis: an update. Acta Derm Venereol. 2022;102:adv00699. https:\/\/doi.org\/10.2340\/actadv.v102.1991.","journal-title":"Acta Derm Venereol"},{"issue":"19","key":"1638_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1638_CR9","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management (CG153). 2017. https:\/\/www.nice.org.uk\/guidance\/cg153. Accessed 16 January 2026."},{"key":"1638_CR10","unstructured":"National Institute for Health and Care Research. Psoriasis and long-term biologic treatments. 2019. https:\/\/www.nihr.ac.uk\/story\/psoriasis-and-long-term-biologic-treatments. Accessed 16 January 2026."},{"key":"1638_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1638_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01796-2","author":"W Hubbard","year":"2022","unstructured":"Hubbard W, Walsh N, Hudson T, Heath A, Dietz J, Rogers G. Development and validation of paired MEDLINE and Embase search filters for cost-utility studies. BMC Med Res Methodol. 2022. https:\/\/doi.org\/10.1186\/s12874-022-01796-2.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"1638_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/hir.12187","volume":"34","author":"L Ayiku","year":"2017","unstructured":"Ayiku L, Levay P, Hudson T, Craven J, Barrett E, Finnegan A, et al. The MEDLINE UK filter: development and validation of a geographic search filter to retrieve research about the UK from OVID MEDLINE. Health Info Libr J. 2017;34(3):200\u201316. https:\/\/doi.org\/10.1111\/hir.12187.","journal-title":"Health Info Libr J"},{"issue":"2","key":"1638_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/hir.12252","volume":"36","author":"L Ayiku","year":"2019","unstructured":"Ayiku L, Levay P, Hudson T, Craven J, Finnegan A, Adams R, et al. The Embase UK filter: validation of a geographic search filter to retrieve research about the UK from OVID Embase. Health Info Libr J. 2019;36(2):121\u201333.","journal-title":"Health Info Libr J"},{"key":"1638_CR15","unstructured":"National Institute for Health and Care Excellence. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455). 2017. https:\/\/www.nice.org.uk\/guidance\/ta455. Accessed 16 Jan 2026."},{"issue":"64","key":"1638_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21640","volume":"21","author":"A Duarte","year":"2017","unstructured":"Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, et al. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technol Assess. 2017;21(64):1\u2013244. https:\/\/doi.org\/10.3310\/hta21640.","journal-title":"Health Technol Assess"},{"key":"#cr-split#-1638_CR17.1","unstructured":"Li T, Higgins J, Deeks J. Chapter 5: Collecting data [last updated October 2019], section 5.2.1. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editors. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane"},{"key":"#cr-split#-1638_CR17.2","unstructured":"2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-05#section-5-2-1. Accessed 16 Jan 2026."},{"key":"1638_CR18","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"issue":"2","key":"1638_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40273-014-0226-y","volume":"33","author":"LM Sawyer","year":"2015","unstructured":"Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. Pharmacoeconomics. 2015;33(2):163\u201377. https:\/\/doi.org\/10.1007\/s40273-014-0226-y.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1638_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40261-021-01089-4","volume":"41","author":"J Barker","year":"2021","unstructured":"Barker J, Baker H, Nadeem A, Gu D-H, Girolomoni G. Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis. Clin Drug Investig. 2021;41(11):1011\u201320. https:\/\/doi.org\/10.1007\/s40261-021-01089-4.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1638_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13696998.2022.2051912","volume":"25","author":"G van de Wetering","year":"2022","unstructured":"van de Wetering G, Ignacio T, Dhanda D, Patel V, Zhang Y, Zhuo J. Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis. J Med Econ. 2022;25(1):421\u20137. https:\/\/doi.org\/10.1080\/13696998.2022.2051912.","journal-title":"J Med Econ"},{"key":"1638_CR22","unstructured":"National Institute for Health and Care Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103). 2009. https:\/\/www.nice.org.uk\/guidance\/ta103. Accessed 16 Jan 2026."},{"issue":"46","key":"1638_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta10460","volume":"10","author":"N Woolacott","year":"2006","unstructured":"Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1\u2013iv. https:\/\/doi.org\/10.3310\/hta10460.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1638_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2133.2008.08863.x","volume":"160","author":"A Lloyd","year":"2009","unstructured":"Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol. 2009;160(2):380\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08863.x.","journal-title":"Br J Dermatol"},{"key":"1638_CR25","unstructured":"National Institute for Health and Care Excellence. Infliximab for the treatment of adults with psoriasis (TA134). 2008. https:\/\/www.nice.org.uk\/guidance\/ta134. Accessed 16 Jan 2026."},{"key":"1638_CR26","unstructured":"Scottish Medicines Consortium. Infliximab 100mg powder for intravenous infusion (Remicade). 2007. https:\/\/scottishmedicines.org.uk\/medicines-advice\/infliximab-100mg-powder-for-intravenous-infusion-remicade-fullsubmission-31806\/. Accessed 16 Jan 2026."},{"issue":"Suppl 1","key":"1638_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3310\/hta13suppl1\/09","volume":"13","author":"E Loveman","year":"2009","unstructured":"Loveman E, Turner D, Hartwell D, Cooper K, Clegg A. Infliximab for the treatment of adults with psoriasis. Health Technol Assess. 2009;13(Suppl 1):55\u201360. https:\/\/doi.org\/10.3310\/hta13suppl1\/09.","journal-title":"Health Technol Assess"},{"key":"1638_CR28","unstructured":"National Institute for Health and Care Excellence. Adalimumab for the treatment of adults with psoriasis (TA146). 2008. https:\/\/www.nice.org.uk\/guidance\/ta146. Accessed 16 Jan 2026."},{"key":"1638_CR29","unstructured":"Scottish Medicines Consortium. Adalimumab (Humira). 2008. https:\/\/scottishmedicines.org.uk\/medicines-advice\/adalimumab-humira-fullsubmission-46808\/. Accessed 16 Jan 2026."},{"issue":"6","key":"1638_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/j.1365-2133.2008.08962.x","volume":"160","author":"S Sizto","year":"2009","unstructured":"Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160(6):1264\u201372. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08962.x.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"1638_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3310\/hta13suppl2-07","volume":"13","author":"D Turner","year":"2009","unstructured":"Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technol Assess. 2009;13(Suppl 2):49\u201354.","journal-title":"Health Technol Assess"},{"key":"1638_CR32","unstructured":"National Institute for Health and Care Excellence. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180). 2017. https:\/\/www.nice.org.uk\/guidance\/ta180. Accessed 16 Jan 2026."},{"key":"1638_CR33","unstructured":"Scottish Medicines Consortium. Ustekinumab (Stelara). 2010. https:\/\/scottishmedicines.org.uk\/medicines-advice\/ustekinumab-stelara-fullsubmission-57209\/. Accessed 16 Jan 2026."},{"issue":"Suppl 3","key":"1638_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3310\/hta13suppl3\/10","volume":"13","author":"E Gospodarevskaya","year":"2009","unstructured":"Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess. 2009;13(Suppl 3):61\u20136. https:\/\/doi.org\/10.3310\/hta13suppl3\/10.","journal-title":"Health Technol Assess"},{"key":"1638_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.04011.x","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Current application of National Institute for Health and Clinical Excellence (NICE) guidance in the management of patients with severe psoriasis: a clinical audit against NICE guidance in seven National Health Service specialist dermatology units in Engla: Biologics in severe psoriasis: audit vs. NICE guidance. Clin Exp Dermatol. 2015. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.04011.x.","journal-title":"Clin Exp Dermatol"},{"key":"1638_CR36","unstructured":"National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis (TA419). 2016. https:\/\/www.nice.org.uk\/guidance\/ta419. Accessed 16 Jan 2026."},{"key":"1638_CR37","unstructured":"Scottish Medicines Consortium. Apremilast (Otezla) plaque psoriasis. 2015. https:\/\/scottishmedicines.org.uk\/medicines-advice\/apremilast-otezla-plaque-psoriasis-fullsubmission-105215\/. Accessed 16 Jan 2026."},{"issue":"1","key":"1638_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2331205X.2018.1495593","volume":"5","author":"A Bewley","year":"2018","unstructured":"Bewley A, Barker J, Mughal F, Cawston H, Damera V, Morris J, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. Cogent Med. 2018;5(1):1\u201323. https:\/\/doi.org\/10.1080\/2331205X.2018.1495593.","journal-title":"Cogent Med."},{"issue":"6","key":"1638_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40273-016-0382-3","volume":"34","author":"S Hinde","year":"2016","unstructured":"Hinde S, Wade R, Palmer S, Woolacott N, Spackman E. Apremilast for the treatment of moderate to severe plaque psoriasis: a critique of the evidence. Pharmacoeconomics. 2016;34(6):587\u201396. https:\/\/doi.org\/10.1007\/s40273-016-0382-3.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR40","unstructured":"National Institute for Health and Care Excellence. Ixekizumab for treating moderate to severe plaque psoriasis (TA442). 2017. https:\/\/www.nice.org.uk\/guidance\/ta442. Accessed 16 Jan 2026."},{"key":"1638_CR41","unstructured":"Scottish Medicines Consortium. Ixekizumab (Taltz). 2017. https:\/\/scottishmedicines.org.uk\/medicines-advice\/ixekizumab-taltz-fullsubmission-122317\/. Accessed 16 Jan 2026."},{"issue":"8","key":"1638_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/13696998.2018.1474747","volume":"21","author":"EC Johansson","year":"2018","unstructured":"Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ. 2018;21(8):810\u201320. https:\/\/doi.org\/10.1080\/13696998.2018.1474747.","journal-title":"J Med Econ"},{"issue":"8","key":"1638_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40273-018-0629-2","volume":"36","author":"BLT Ramaekers","year":"2018","unstructured":"Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, et al. Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(8):917\u201327. https:\/\/doi.org\/10.1007\/s40273-018-0629-2.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR44","unstructured":"National Institute for Health and Care Excellence. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475). 2017. https:\/\/www.nice.org.uk\/guidance\/ta475. Accessed 16 Jan 2026."},{"key":"1638_CR45","doi-asserted-by":"publisher","DOI":"10.30637\/2024.24-067","author":"Scottish Medicines Consortium","year":"2018","unstructured":"Scottish Medicines Consortium. Dimethyl fumarate (Skilarence). Rev Med Brux. 2018. https:\/\/doi.org\/10.30637\/2024.24-067.","journal-title":"Rev Med Brux"},{"key":"1638_CR46","unstructured":"National Institute for Health and Care Excellence. Brodalumab for treating moderate to severe plaque psoriasis (TA511). 2018. https:\/\/www.nice.org.uk\/guidance\/ta511. Accessed 16 Jan 2026."},{"key":"1638_CR47","unstructured":"Scottish Medicines Consortium. Brodalumab (Kyntheum). 2018. https:\/\/scottishmedicines.org.uk\/medicines-advice\/brodalumab-kyntheum-resubmission\/. Accessed 16 Jan 2026."},{"issue":"2","key":"1638_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40273-018-0698-2","volume":"37","author":"R Wade","year":"2019","unstructured":"Wade R, Grosso A, South E, Rothery C, Saramago P, Schmitt L, et al. Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an evidence review group evaluation of a NICE single technology appraisal. Pharmacoeconomics. 2019;37(2):131\u20139. https:\/\/doi.org\/10.1007\/s40273-018-0698-2.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR49","unstructured":"National Institute for Health and Care Excellence. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574). 2019. https:\/\/www.nice.org.uk\/guidance\/ta574. Accessed 16 Jan 2026."},{"key":"1638_CR50","unstructured":"Scottish Medicines Consortium. Certolizumab pegol (Cimzia). 2019. https:\/\/scottishmedicines.org.uk\/medicines-advice\/certolizumab-pegol-cimzia-fullsubmission-smc2132\/. Accessed 16 Jan 2026."},{"key":"1638_CR51","unstructured":"National Institute for Health and Care Excellence. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575). 2019. https:\/\/www.nice.org.uk\/guidance\/ta575. Accessed 16 Jan 2026."},{"key":"1638_CR52","unstructured":"Scottish Medicines Consortium. Risankizumab (Skyrizi). 2019. https:\/\/scottishmedicines.org.uk\/medicines-advice\/risankizumab-skyrizi-full-smc2196\/. Accessed 16 January 2026."},{"key":"1638_CR53","unstructured":"National Institute for Health and Care Excellence. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907). 2023. https:\/\/www.nice.org.uk\/guidance\/ta907. Accessed 16 Jan 2026."},{"key":"1638_CR54","unstructured":"Scottish Medicines Consortium. Deucravacitinib (Sotyktu). 2023. https:\/\/scottishmedicines.org.uk\/medicines-advice\/deucravacitinib-sotyktu-full-smc2581\/. Accessed 16 Jan 2026."},{"issue":"31","key":"1638_CR55","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta10310","volume":"10","author":"N Woolacott","year":"2006","unstructured":"Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2006;10(31):iii\u2013239. https:\/\/doi.org\/10.3310\/hta10310.","journal-title":"Health Technol Assess"},{"issue":"8","key":"1638_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kel147","volume":"45","author":"NJ Bansback","year":"2006","unstructured":"Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford). 2006;45(8):1029\u201338. https:\/\/doi.org\/10.1093\/rheumatology\/kel147.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1638_CR57","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/rheumatology\/kem221","volume":"46","author":"Y Bravo Vergel","year":"2007","unstructured":"Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford). 2007;46(11):1729\u201335. https:\/\/doi.org\/10.1093\/rheumatology\/kem221.","journal-title":"Rheumatology (Oxford)"},{"key":"1638_CR58","unstructured":"National Institute for Health and Care Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199). 2010. https:\/\/www.nice.org.uk\/guidance\/ta199. Accessed 16 Jan 2026."},{"issue":"10","key":"1638_CR59","doi-asserted-by":"publisher","first-page":"i","DOI":"10.3310\/hta15100","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):i\u2013329. https:\/\/doi.org\/10.3310\/hta15100.","journal-title":"Health Technol Assess"},{"issue":"1","key":"1638_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jval.2010.10.016","volume":"14","author":"E Cummins","year":"2011","unstructured":"Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health. 2011;14(1):15\u201323. https:\/\/doi.org\/10.1016\/j.jval.2010.10.016.","journal-title":"Value Health."},{"key":"1638_CR61","unstructured":"Scottish Medicines Consortium. Adalimumab (Humira). 2005. https:\/\/scottishmedicines.org.uk\/medicines-advice\/adalimumab-humira-fullsubmission-21805\/. Accessed 16 Jan 2026."},{"issue":"Suppl 4","key":"1638_CR62","doi-asserted-by":"publisher","first-page":"iv39","DOI":"10.1093\/rheumatology\/ker245","volume":"50","author":"L Bojke","year":"2011","unstructured":"Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford). 2011;50(Suppl 4):iv39\u201347. https:\/\/doi.org\/10.1093\/rheumatology\/ker245.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1638_CR63","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jval.2011.04.007","volume":"14","author":"D Epstein","year":"2011","unstructured":"Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value Health. 2011;14(6):793\u20139. https:\/\/doi.org\/10.1016\/j.jval.2011.04.007.","journal-title":"Value Health."},{"issue":"5","key":"1638_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1524-4733.2010.00709.x","volume":"13","author":"L Bojke","year":"2010","unstructured":"Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value Health. 2010;13(5):557\u201364. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00709.x.","journal-title":"Value Health."},{"key":"1638_CR65","unstructured":"National Institute for Health and Care Excellence. Golimumab for the treatment of psoriatic arthritis (TA220). 2011. https:\/\/www.nice.org.uk\/guidance\/ta220. Accessed 16 Jan 2026."},{"issue":"6","key":"1638_CR66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","volume":"13","author":"E Cummins","year":"2012","unstructured":"Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2012;13(6):801\u20139. https:\/\/doi.org\/10.1007\/s10198-011-0335-x.","journal-title":"Eur J Health Econ"},{"issue":"Suppl 1","key":"1638_CR67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3310\/hta15suppl1\/10","volume":"15","author":"H Yang","year":"2011","unstructured":"Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, et al. Golimumab for the treatment of psoriatic arthritis. Health Technol Assess. 2011;15(Suppl 1):87\u201395. https:\/\/doi.org\/10.3310\/hta15suppl1\/10.","journal-title":"Health Technol Assess"},{"issue":"4","key":"1638_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/11595920-000000000-00000","volume":"30","author":"H Yang","year":"2012","unstructured":"Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257\u201370. https:\/\/doi.org\/10.2165\/11595920-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR69","unstructured":"National Institute for Health and Care Excellence. Ustekinumab for treating active psoriatic arthritis (TA340). 2017. https:\/\/www.nice.org.uk\/guidance\/ta340. Accessed 16 Jan 2026."},{"key":"1638_CR70","unstructured":"Scottish Medicines Consortium. Ustekinumab (Stelara). 2014. https:\/\/scottishmedicines.org.uk\/medicines-advice\/ustekinumab-stelara-fullsubmission-94414\/. Accessed 16 Jan 2026."},{"issue":"4","key":"1638_CR71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40273-015-0350-3","volume":"34","author":"J O'Connor","year":"2016","unstructured":"O\u2019Connor J, Rice S, Smith A, Rodgers M, Lopez RR, Craig D, et al. The clinical and cost effectiveness of ustekinumab for the treatment of psoriatic arthritis: a critique of the evidence. Pharmacoeconomics. 2016;34(4):337\u201348. https:\/\/doi.org\/10.1007\/s40273-015-0350-3.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR72","unstructured":"National Institute for Health and Care Excellence. Apremilast for treating active psoriatic arthritis (TA433). 2017. https:\/\/www.nice.org.uk\/guidance\/ta433. Accessed 16 Jan 2026."},{"key":"1638_CR73","unstructured":"Scottish Medicines Consortium. Apremilast (Otezla) psoriatic arthritis. 2015. https:\/\/scottishmedicines.org.uk\/medicines-advice\/apremilast-otezla-psoriatic-arthritis-fullsubmission-105315\/. Accessed 16 January 2026."},{"issue":"11","key":"1638_CR74","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40273-016-0419-7","volume":"34","author":"E Sideris","year":"2016","unstructured":"Sideris E, Corbett M, Palmer S, Woolacott N, Bojke L. The clinical and cost effectiveness of apremilast for treating active psoriatic arthritis: a critique of the evidence. Pharmacoeconomics. 2016;34(11):1101\u201310. https:\/\/doi.org\/10.1007\/s40273-016-0419-7.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR75","unstructured":"National Institute for Health and Care Excellence. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445). 2017. https:\/\/www.nice.org.uk\/guidance\/ta445. Accessed 16 Jan 2026."},{"issue":"56","key":"1638_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21560","volume":"21","author":"M Corbett","year":"2017","unstructured":"Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, et al. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017;21(56):1\u2013326. https:\/\/doi.org\/10.3310\/hta21560.","journal-title":"Health Technol Assess"},{"key":"1638_CR77","unstructured":"Scottish Medicines Consortium. Certolizumab pegol (Cimzia). 2014. https:\/\/scottishmedicines.org.uk\/medicines-advice\/certolizumab-pegol-cimzia-fullsubmission-97314\/. Accessed 16 Jan 2026."},{"issue":"7","key":"1638_CR78","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-018-0674-x","volume":"36","author":"V Buchanan","year":"2018","unstructured":"Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, et al. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018;36(7):867\u201378. https:\/\/doi.org\/10.1007\/s40273-018-0674-x.","journal-title":"Pharmacoeconomics"},{"key":"1638_CR79","unstructured":"National Institute for Health and Care Excellence. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537). 2018. https:\/\/www.nice.org.uk\/guidance\/ta537. Accessed 16 Jan 2026."},{"issue":"4","key":"1638_CR80","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s41669-020-00202-1","volume":"4","author":"B Schweikert","year":"2020","unstructured":"Schweikert B, Malmberg C, Akerborg O, Kumar G, Nott D, Kiri S, et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate-to-severe psoriasis in the UK. PharmacoEconomics - Open. 2020;4(4):635\u201348. https:\/\/doi.org\/10.1007\/s41669-020-00202-1.","journal-title":"PharmacoEconomics - Open"},{"key":"1638_CR81","unstructured":"National Institute for Health and Care Excellence. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543). 2018. https:\/\/www.nice.org.uk\/guidance\/ta543. Accessed 16 Jan 2026."},{"key":"1638_CR82","unstructured":"Scottish Medicines Consortium. Tofacitinib (Xeljanz). 2019. https:\/\/scottishmedicines.org.uk\/medicines-advice\/tofacitinib-xeljanz-psoriatic-arthritis-fullsubmission-smc2116\/. Accessed 16 Jan 2026."},{"key":"1638_CR83","unstructured":"National Institute for Health and Care Excellence. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768). 2022. https:\/\/www.nice.org.uk\/guidance\/ta768. Accessed 16 Jan 2026."},{"key":"1638_CR84","unstructured":"National Institute for Health and Care Excellence. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815). 2022. https:\/\/www.nice.org.uk\/guidance\/ta815. Accessed 16 Jan 2026."},{"key":"1638_CR85","unstructured":"Scottish Medicines Consortium. Guselkumab (Tremfya). 2021. https:\/\/scottishmedicines.org.uk\/medicines-advice\/guselkumab-tremfya-full-smc2360\/. Accessed 16 Jan 2026."},{"issue":"6","key":"1638_CR86","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s13555-021-00602-z","volume":"11","author":"K Fahrbach","year":"2021","unstructured":"Fahrbach K, Sarri G, Phillippo DM, Neupane B, Martel SE, Kiri S, et al. Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. Dermatol Ther (Heidelb). 2021;11(6):1965\u201398. https:\/\/doi.org\/10.1007\/s13555-021-00602-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1638_CR87","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/ard.61.9.793","volume":"61","author":"P Geborek","year":"2002","unstructured":"Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61(9):793\u20138. https:\/\/doi.org\/10.1136\/ard.61.9.793.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1638_CR88","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244\u201352. https:\/\/doi.org\/10.1111\/bjd.13343.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1638_CR89","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2133.2010.09944.x","volume":"163","author":"A Fonia","year":"2010","unstructured":"Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807\u201316. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09944.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1638_CR90","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","volume":"42","author":"G Kobelt","year":"2003","unstructured":"Kobelt G, J\u00f6nsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003;42(2):326\u201335. https:\/\/doi.org\/10.1093\/rheumatology\/keg107.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1638_CR91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/09546639909055907","volume":"10","author":"T Poyner","year":"1999","unstructured":"Poyner T, Wall A, Adnitt P, Menday A. Economic impact of psoriasis treatment on the patient and on the National Health Service. J Dermatol Treat. 1999;10(1):25\u20139. https:\/\/doi.org\/10.3109\/09546639909055907.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1638_CR92","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1046\/j.1365-2133.2002.04920.x","volume":"147","author":"M Hartman","year":"2002","unstructured":"Hartman M, Prins M, Swinkels OQ, Severens JL, De Boo T, Van Der Wilt GJ, et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol. 2002;147(3):538\u201344. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04920.x.","journal-title":"Br J Dermatol"},{"key":"1638_CR93","unstructured":"National Institute for Health and Care Excellence. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935). 2023. https:\/\/www.nice.org.uk\/guidance\/ta935. Accessed 26 Jan 2026."},{"key":"1638_CR94","unstructured":"National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis (TA534). 2018. https:\/\/www.nice.org.uk\/guidance\/ta534. Accessed 26 Jan 2026."},{"key":"1638_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljag098","author":"DB Phan","year":"2026","unstructured":"Phan DB, Laws P, Smith CH, Griffiths CEM, Kirby B, Hughes O, et al. Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register. Br J Dermatol. 2026. https:\/\/doi.org\/10.1093\/bjd\/ljag098.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1638_CR96","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337. https:\/\/doi.org\/10.1111\/bjd.19039.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1638_CR97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjd.18623","volume":"183","author":"RB Warren","year":"2020","unstructured":"Warren RB, Barker J, Finlay AY, Burden AD, Kirby B, Armendariz Y, et al. Secukinumab for patients failing previous tumour necrosis factor-\u03b1 inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2020;183(1):60\u201370. https:\/\/doi.org\/10.1111\/bjd.18623.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1638_CR98","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/jcm13092691","volume":"13","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Martora F, Vallone Y, Guerrasio G, Potestio L. Long-term efficacy and safety of guselkumab in psoriasis patients who failed anti-IL17: a two-year real-life study. J Clin Med. 2024;13(9):2691. https:\/\/doi.org\/10.3390\/jcm13092691.","journal-title":"J Clin Med"},{"issue":"2","key":"1638_CR99","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1111\/jdv.20192","volume":"39","author":"MW Nam","year":"2025","unstructured":"Nam MW, Yoon HS. Comparative analysis of switching strategies for IL-23 and IL-17A inhibitors for the treatment of psoriasis: Interclass switching outperforms intraclass switching. J Eur Acad Dermatol Venereol. 2025;39(2):e144\u20136. https:\/\/doi.org\/10.1111\/jdv.20192.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1638_CR100","unstructured":"NHS North East London. North East London high-cost drugs treatment pathway for psoriasis 2023. https:\/\/primarycare.northeastlondon.icb.nhs.uk\/wp-content\/uploads\/2023\/06\/NEL-Psoriasis-pathway-final-version.pdf. Accessed 26 Jan 2026."},{"key":"1638_CR101","unstructured":"Greater Manchester Medicines Management Group. Commissioning statement for use of high cost drugs for psoriasis and atopic dermatitis in adults under dermatology services in Greater Manchester. 2025. https:\/\/gmmmg.nhs.uk\/wp-content\/uploads\/2025\/05\/Commissioning-statement-for-HCDs-for-psoriasis-and-AD-in-adults-under-dermatology-services-in-GM-1.0.pdf. Accessed 26 Jan 2026."},{"issue":"Suppl 1","key":"1638_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","volume":"164","author":"RB Warren","year":"2011","unstructured":"Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164(Suppl 1):1\u201314. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10280.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1638_CR103","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Armstrong A, Chow M, DeBusk L, Brad G, Gottlieb AB, et al. The association between obesity and efficacy of psoriasis therapies: An expert consensus panel. J Am Acad Dermatol. 2025;92(4):807\u201315. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.016.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1638_CR104","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","volume":"51","author":"ZS Yang","year":"2016","unstructured":"Yang ZS, Lin NN, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016;51(2):240\u20137. https:\/\/doi.org\/10.1007\/s12016-016-8560-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"1638_CR105","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/art.41923","volume":"74","author":"L Penso","year":"2022","unstructured":"Penso L, Bergqvist C, Meyer A, Herlemont P, Weill A, Zureik M, et al. Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis\/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the french national health data system. Arthritis Rheumatol. 2022;74(2):244\u201352. https:\/\/doi.org\/10.1002\/art.41923.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1638_CR106","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","volume":"39","author":"L Motedayen Aval","year":"2025","unstructured":"Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025;39(10):1785\u201395. https:\/\/doi.org\/10.1111\/jdv.20739.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1638_CR107","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40273-016-0455-3","volume":"35","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Pan F, Sorensen S. Modeling Treatment Sequences in Pharmacoeconomic Models. Pharmacoeconomics. 2017;35(1):15\u201324. https:\/\/doi.org\/10.1007\/s40273-016-0455-3.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1638_CR108","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133. Value Health. 2012;15(6):812\u201320. https:\/\/doi.org\/10.1016\/j.jval.2012.06.014.","journal-title":"Value Health."},{"issue":"4","key":"1638_CR109","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s10067-025-07368-1","volume":"44","author":"O Xie","year":"2025","unstructured":"Xie O, Wu M, Li A, Meng K, Xiang H, Tan C, et al. Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis. Clin Rheumatol. 2025;44(4):1597\u2013606. https:\/\/doi.org\/10.1007\/s10067-025-07368-1.","journal-title":"Clin Rheumatol"},{"key":"1638_CR110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3310\/LVUQ5853","volume":"10","author":"L Cordingley","year":"2022","unstructured":"Cordingley L, Nelson PA, Davies L, Ashcroft D, Bundy C, Chew-Graham C, et al. Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants Appl Res. 2022;10:3. https:\/\/doi.org\/10.3310\/LVUQ5853.","journal-title":"Programme Grants Appl Res."},{"issue":"35","key":"1638_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1\u2013610. https:\/\/doi.org\/10.3310\/hta20350.","journal-title":"Health Technol Assess"},{"issue":"4","key":"1638_CR112","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/dme.12371","volume":"31","author":"P Thokala","year":"2014","unstructured":"Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, et al. Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2014;31(4):477\u201386. https:\/\/doi.org\/10.1111\/dme.12371.","journal-title":"Diabet Med"},{"issue":"1","key":"1638_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/gjdl0327","volume":"30","author":"D Lee","year":"2026","unstructured":"Lee D, Muthukumar M, Lovell A, Farmer C, Burns D, Matthews J, et al. Treatments for renal cell carcinoma: NICE pilot treatment pathways appraisal. Health Technol Assess. 2026;30(1):1\u2013221. https:\/\/doi.org\/10.3310\/gjdl0327.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1638_CR114","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13696998.2017.1384737","volume":"21","author":"R Goeree","year":"2018","unstructured":"Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018;21(2):163\u201373. https:\/\/doi.org\/10.1080\/13696998.2017.1384737.","journal-title":"J Med Econ"},{"key":"1638_CR115","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.vhri.2019.03.002","volume":"20","author":"E Aiello","year":"2019","unstructured":"Aiello E, Bianculli PM, Bhattacharyya D, Gunda P, Citera G. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective. Value Health Reg Issues. 2019;20:86\u201394. https:\/\/doi.org\/10.1016\/j.vhri.2019.03.002.","journal-title":"Value Health Reg Issues."},{"key":"1638_CR116","unstructured":"Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. 2018. https:\/\/icer.org\/assessment\/psoriasis-2018\/. Accessed 27 Jan 2026."},{"key":"1638_CR117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/ceor.s7348","volume":"1","author":"GL Colombo","year":"2009","unstructured":"Colombo GL, Di Matteo S, Peris K, Fargnoli MC, Esposito M, Mazzotta A, et al. A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. Clinicoecon Outcomes Res. 2009;1:53\u20139. https:\/\/doi.org\/10.2147\/ceor.s7348.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"1","key":"1638_CR118","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1080\/13696998.2025.2515771","volume":"28","author":"G van de Wetering","year":"2025","unstructured":"van de Wetering G, Kim H, Roberts D, Hikichi Y, Smith M, Tada Y. A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan. J Med Econ. 2025;28(1):922\u201333. https:\/\/doi.org\/10.1080\/13696998.2025.2515771.","journal-title":"J Med Econ"},{"key":"1638_CR119","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.vhri.2022.10.005","volume":"34","author":"P Dilokthornsakul","year":"2023","unstructured":"Dilokthornsakul P, Sawangjit R, Osiri M, Chiowchanwisawakit P, Louthrenoo W, Permsuwan U. Cost-utility analysis of biologic disease-modifying antirheumatic drugs for patients with psoriatic arthritis in Thailand. Value Health Reg Issues. 2023;34:40\u20137. https:\/\/doi.org\/10.1016\/j.vhri.2022.10.005.","journal-title":"Value Health Reg Issues."},{"issue":"1","key":"1638_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189765","volume":"13","author":"C Kromer","year":"2018","unstructured":"Kromer C, Celis D, Sonntag D, Peitsch WK. Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PLoS ONE. 2018;13(1):e0189765. https:\/\/doi.org\/10.1371\/journal.pone.0189765.","journal-title":"PLoS ONE"},{"issue":"3","key":"1638_CR121","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.13486","volume":"172","author":"MP Hamilton","year":"2015","unstructured":"Hamilton MP, Ntais D, Griffiths CEM, Davies LM. Psoriasis treatment and management - a systematic review of full economic evaluations. Br J Dermatol. 2015;172(3):574\u201383. https:\/\/doi.org\/10.1111\/bjd.13486.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1638_CR122","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40273-014-0244-9","volume":"33","author":"W Zhang","year":"2015","unstructured":"Zhang W, Islam N, Ma C, Anis AH. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327\u201340. https:\/\/doi.org\/10.1007\/s40273-014-0244-9.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1638_CR123","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40273-014-0130-5","volume":"32","author":"J Mauskopf","year":"2014","unstructured":"Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: A systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014;32(4):395\u2013409. https:\/\/doi.org\/10.1007\/s40273-014-0130-5.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1638_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000339865","volume":"225","author":"FRA Pereira","year":"2012","unstructured":"Pereira FRA, Basra MKA, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012;225(1):45\u201353. https:\/\/doi.org\/10.1159\/000339865.","journal-title":"Dermatology"},{"issue":"4 Suppl 73","key":"1638_CR125","first-page":"S126","volume":"30","author":"PA Cortesi","year":"2012","unstructured":"Cortesi PA, Scalone L, D\u2019Angiolella L, Belisari A, Fusco F, Olivieri I, et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S126\u201331.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"1638_CR126","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-024-01428-1","volume":"42","author":"IC Antonazzo","year":"2024","unstructured":"Antonazzo IC, Gribaudo G, La Vecchia A, Ferrara P, Piraino A, Cortesi PA, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: an updated systematic literature review. Pharmacoeconomics. 2024;42(12):1329\u201343. https:\/\/doi.org\/10.1007\/s40273-024-01428-1.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1638_CR127","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","volume":"36","author":"LS D'Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics. 2018;36(5):567\u201389. https:\/\/doi.org\/10.1007\/s40273-018-0618-5.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1638_CR128","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/bjd.12261","volume":"168","author":"L Sawyer","year":"2013","unstructured":"Sawyer L, Samarasekera EJ, Wonderling D, Smith CH. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol. 2013;168(5):1095\u2013105. https:\/\/doi.org\/10.1111\/bjd.12261.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1638_CR129","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/acr.23293","volume":"70","author":"JL O'Dwyer","year":"2018","unstructured":"O\u2019Dwyer JL, Meads DM, Hulme CT, McParland L, Brown S, Coates LC, et al. Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial. Arthritis Care Res. 2018;70(3):462\u20138. https:\/\/doi.org\/10.1002\/acr.23293.","journal-title":"Arthritis Care Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01638-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:42:41Z","timestamp":1790343761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01638-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":130,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01638-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analysed during this study are included in this published article or the Supplementary Information.","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TC, DBP, RW, ZY, and GR developed the review protocol. TC conducted the literature searches. Screening was performed by TC and AC. TC conducted the data extraction and quality appraisal, and AC checked a sample for accuracy. TC wrote the first draft of the manuscript and all authors provided comments. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}